• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Biorepository Science for Applied Medicine >Biobanking metastases and biopsy specimens for personalized medicine
【24h】

Biobanking metastases and biopsy specimens for personalized medicine

机译：用于个性化医学的生物库转移和活检标本

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Metastasis often develops in cancer patients despite improvements in surgery, chemotherapy, and radiation therapy. Biopsy specimens of metastatic lesions are extremely valuable materials for monitoring disease progression, assessing therapeutic outcome, and delivering personalized medicine. Biobanking high-quality human metastases and biopsy tissue specimens, derivatives, liquid biopsy specimens, and associated patient clinical information provides a fundamental scientific infrastructure for personalized medicine. Biomarkers specifically associated with an individual tumor have a very significant impact on personalized therapy. Therefore, the availability of a large collection of metastases and biopsy specimens from cancer patients with well-annotated patient clinical and pathological data is a critical requirement for personalized medicine. While current efforts have been made to develop cancer biorepositories around the world for personalized medicine, the majority of biospecimens in these biorepositories are primary tumor samples. The procurement, processing, and storage of human metastases and biopsy specimens remain challenging, since metastatic tumors are almost incurable and most are not the object of surgical resection. Thus, biobanking metastases and biopsy specimens provides a unique role to facilitate the molecular analysis of metastatic tumors, and the identification and validation of therapeutic targets and the discovery and validation of biomarkers that are associated with personalized treatment. This review provides an overview of the development of a metastases and biopsy specimens biobank, analyzes the challenges, and discusses the specific needs regarding this distinct type of biobank development for advancement of personalized medicine.
机译：摘要：尽管外科手术，化学疗法和放射疗法有所改善，但癌症患者中经常发生转移。转移性病变的活检标本是监测疾病进展，评估治疗结果和提供个性化药物的极有价值的材料。高质量的人类转移瘤和活检组织标本，衍生物，液体活检标本以及相关患者临床信息的生物存储为个性化医学提供了基础科学基础设施。与单个肿瘤特异性相关的生物标志物对个性化治疗具有非常重要的影响。因此，从癌症患者那里获得大量转移和活检标本，以及具有良好注释的患者临床和病理数据的可用性是个性化医学的关键要求。尽管目前已经在世界范围内努力开发用于个体化医学的癌症生物储存库，但是这些生物储存库中的大多数生物标本都是原发性肿瘤样品。人类转移灶和活检标本的采购，加工和存储仍然具有挑战性，因为转移性肿瘤几乎是无法治愈的，而且大多数不是手术切除的对象。因此，生物库转移和活检标本在促进转移性肿瘤的分子分析，治疗靶标的鉴定和验证以及与个性化治疗相关的生物标志物的发现和验证方面具有独特的作用。这篇综述概述了转移和活检标本生物库的发展，分析了挑战，并讨论了有关这种独特类型的生物库发展以促进个性化医学的特殊需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号